Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

BACKGROUND: A recent and provocative meta-analysis, based on few outcome events, suggested that rosiglitazone increased cardiovascular mortality and myocardial infarction. However, results of meta-analyses of trials with sparse events, often performed when examining uncommon adverse effects due to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Jan O, Beyene, Joseph, Adhikari, Neill KJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649945/
https://www.ncbi.nlm.nih.gov/pubmed/19134216
http://dx.doi.org/10.1186/1756-0500-2-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649945/
https://www.ncbi.nlm.nih.gov/pubmed/19134216
http://dx.doi.org/10.1186/1756-0500-2-5

Ejemplares similares